| Pharmaceutical Information |
| Drug Name |
Pegaptanib |
| Drug ID |
BADD_D01690 |
| Description |
Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability.
Pegaptanib was granted FDA approval on 17 September 2004.[L17903] |
| Indications and Usage |
For the treatment of neovascular (wet) age-related macular degeneration. |
| Marketing Status |
approved; investigational |
| ATC Code |
S01LA03 |
| DrugBank ID |
DB04895
|
| KEGG ID |
D05386
|
| MeSH ID |
C495058
|
| PubChem ID |
56603655
|
| TTD Drug ID |
D0UF9W
|
| NDC Product Code |
Not Available |
| UNII |
2H1PA8H1EN
|
| Synonyms |
pegaptanib | Macugen | pegaptanib sodium |
|
| Chemical Information |
| Molecular Formula |
C22H44N3O10P |
| CAS Registry Number |
222716-86-1 |
| SMILES |
COCCOC(=O)NCCCCC(C(=O)NCCCCCCCOP(=O)(C)O)NC(=O)OCCOC |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
